STOCKS TELEGRAPH

Author: Mustafa Bin Tariq

  • GoHealth Inc (GOCO) stock plunged in the pre-market. Here’s why

    The stock of GoHealth Inc (GOCO) closed the recent trading session at $1.45, losing 27.14% from the previous trading session. The stock of GOCO further lost 14.57% in the pre-market, to $1.7. The firm published the preluded fiscal performance for Q4 and FY21. GOCO also filed for form 4 on 15 February 2022. The form refers to the change in beneficial ownership of securities.

    GOCO’s FY21 expectations

    GoHealth Inc published the preluded fiscal performance of its Q4 and FY21 on 1 March 2022. The main points are

    • GOCO estimates the sales for Q4 of FY21 to be between $425 million and $470 million. Also, Yearly sales are estimated to be in the range of $1.04 billion and $1.08 billion.
    • The firm expects the total loss for Q4 of FY21 to be in the middle of $38.8 million and $52.7 million. While the firm estimates yearly loss to be in the range of $141 million and $155 million.
    • GOCO estimates the adjusted EBITDA to in the range of -$5.5 million and $8.5 million. Further, the annual adjusted EBITDA is estimated to be in between $26.5 million and $40.5 million.

    CEO Remarks

    The CEO of GoHealth Inc (GOCO), Clint Jones, commented that he appreciates each worker for the excellent endeavours during a difficult condition. He further added that they encountered significant tensions because of the expanded customer shopping and surprisingly high labor price.

    Further, Mr. Jones concluded that he anticipates giving more insight concerning their 2021 presentation alongside their 2022 direction. The earnings call for GOCO will be on 15 March 2022.

    About GOCO

    Gohealth Inc is an advanced wellbeing organization, which takes part in the arrangement of insurance services. The firm works in four sections: Medicare-Internal, Medicare-External, Individual and family plans Internal, and IFP External. The firm has a market cap of $638.21 million and 320.71 million pending shares. GOCO has its headquarter in Chicago, Illinois, United States of America (USA).

  • Guardion Health Sciences Inc (GHSI) stock is gaining in the pre-market. Here’s why

    The stock of Guardion Health Sciences Inc (GHSI) closed the recent trading session at $0.28, gaining 47.84% from the previous session. During the last check, the stock of GHSI remained bullish in the pre-market, gaining 49.29% to $0.418. GHSI declared the closing of its preceding public offer. The company also filed for the form SC 13G with SEC on 28 February 2022.

    Guardion Health Sciences Inc (GHSI) is a clinical nourishment and diagnostics organization. GHSI creates clinical food varieties and clinical gadgets in the visual wellbeing space and creates nutraceutical items to give steady medical advantages to clients. The organization’s clinical gadgets are utilized to quantify visual capacity and certain physical elements of the eye that recognize early sickness. The firm has a market cap of $6.83mn and 24.43mn shares pending. The firm has its headquarter in Houston, Texas, United States of America (USA).

    GHSI’s News

    On 23 February 2022, Guardion Inc declared the closing of its preceding public offering of 37 million stocks. GHSI issued warrants A and warrants B to buy up to 37 million of the normal stock. The price of the normal stock was $0.30 per stock. Further, warrant A had the price of $0.37 per stock with validity for five years from the issue date. While the warrant B had the price of $0.37 with a validity for 18 months from the issue date. Moreover, the total amount from the public offering was $11 million.

    On February 14, 2022, GHSI reported about the release of its Viactiv Omega Boost gel bites. The Omega gel bites are intended to give all out the body support, including cardiovascular, neurological, joint, and visual wellbeing. The CEO of GHSI, Bret Scholtes, stated that they are eager to have the option to offer steady supplements under the reliable Viactiv brand. He further added that they anticipate being a dependable asset for the nourishing enhancement needs of their clients.

  • Bionano Genomics Inc (BNGO) stock lost 8.8% in the after-market. Here’s why

    The stock of Bionano Genomics Inc (BNGO) closed the recent trading session at $2.16, 0.93% more than the previous trading session. On the last check, the stock of BNGO followed a bearish pattern in the after-market, losing 8.8% to $1.97. BNGO published the financial performance for its Q4 and FY21.

    BNGO’s FY21 performance

    On 1 March 2022, Bionano Genomics published the financial performance for the period Q4 and FY21, which ended on 31 December 2021. The company posted revenue of $6.3 million in Q4 of FY21 compared to $3.9 million in the corresponding period of last year. This marks a growth of 57.9%. The yearly revenue expanded by 111.4% to $17.9 million in 2021 from $8.5 million in 2020. Total loss of BNGO grew by 95.6% in Q4 of FY21 to $22.9 million versus $11.7 million in Q4 of FY20. The yearly loss expanded by 76.2% in 2021 to $72.4 million. BNGO’s operating loss increased by 158.7% in Q4 of FY21 to $28.7 million against $11.1 million in the same year-ago period. Also, the yearly operating loss expanded by 99.9% in 2021 to $77.1 million.

    The company sold 12,518 flow cells in the fiscal year 2021. The Saphyr system of the company grew by 14% to 164 bases in Q4 of FY21 versus 141 bases in Q4 of FY20. Further, BNGO finished the principal model for the single-molecule imaging framework for OGM. Moreover, Bionano obtained BioDiscovery, Inc, including its industry-driving software, NxClinical.

    CEO Remarks

    The CEO of Bionano Genomics, Erik Holmlin, stated that they accept 2021 was ground-breaking for Bionano. He further added that they added top-notch software through the addition of BioDiscovery and fundamentally improved their programming aptitude.

    Mr. Holmlin concluded that they start in 2022 hoping to proceed with the energy that is enhanced throughout 2021.

    About BNGO

    Bionano Genomics (BNGO) is a supplier of genome investigation arrangements. The investigations can empower analysts and clinicians to further uncover answers to inquiries in medication. The company has a market cap of $624.6 million and 289.18 million pending shares. BNGO have a headquarter in San Diego, California, the United States of America (USA),

  • Inovio Pharmaceuticals Inc (INO) stock nosedived in the after-hours. Here’s why

    The stock of Inovio Pharmaceuticals Inc (INO) nosedived in the after-market, following the announcement of financial performance for Q4 and FY21. INO stock lost 12.35% in the after-hours, to $2.84. The stock of INO closed the recent trading session at $3.24, with no change from the previous trading session. Inovia also filed the forms 10-K, 4, and S-8 with SEC on 1 March 2022.

    Inovia Pharmaceuticals Inc is a biotechnology organization centered around the disclosure, production, and commercialization of manufactured DNA items for treating malignant growths and infections. The company has a market capitalization of $681.6 million with 210.39 million pending shares. INO has its headquarter in San Diego, California, United States of America (USA).

    INO’s FY21 highlights

    Inovia declared the financial performance for its Q4 and FY21, on 1 March 2022. The financial highlights for Q4 and FY21 are

    • INO’s revenue reduced by 76% to $1.7 million in 2021 versus $7.4 million in 2020. The Q4 revenue for FY21 was $0.8 million compared to $5.6 million in Q4 of FY20.
    • The company reported a loss of $106.9 million in Q4 of FY21 versus $24.3 million in Q4 of FY20. The yearly loss expanded by 81.3% to $303.6 million in 2021 compared to $167.4 million in 2020.
    • Moreover, the loss of $0.50 and $1.45 per stock in Q4 and FY21, respectively.
    • Cash and cash equivalents of the company were reduced by 71.6% to $71.1 million in 2021 from $250.7 million in 2022.

    CEO Remarks

    The CEO of Inovio Pharmaceuticals (INO), DR J. Joseph Kim, commented that COVID-19 addresses a  constant danger to the wellbeing of the community worldwide. He added that compared to their COVID-19 struggles, they are happy with the clinical progress of their DNA-based medications.

    DR Kim concluded that they have finished enlistment in a Phase 1b preliminary for Lassa fever. Also, a Phase 1b preliminary for an Ebola vaccine, as well as a Phase 2 preliminary for Middle East Respiratory Syndrome (MERS).

  • DSS Inc (DSS) stock lost 6.54% in the pre-market. Here’s why

    The stock of DSS Inc (DSS) closed the recent trading session at $0.56, gaining 47.24% from the previous trading session. On the last check, the stock lost 6.54% in the pre-market, to $0.53. DSS Inc issued a letter to its investors on February 28, 2022.

    DSS is a global organization working in blockchain security, marketing, medical care, land, banking, loaning, and finance. Its plan of action depends on a circulation framework in which investors get the shares in its auxiliaries. With a market cap of $45.14 million, the company has 79.75 million shares pending. The headquarter of DSS is in Victor, New York, United States of America (USA).

    DSS News

    On 28 February 2022, DSS issued a letter to its investors. The letter states that the energetic work of their devoted team has prompted critical value creation and has put them in a strong direction for sped-up development. The company said that in only two years, they added eight business lines. They also developed resources for more than $219 million, including $69 million for cash. Through three fruitful public offerings, the company raised total returns of more than $121 million.

    One of DSS’s subsidiaries, American Pacific Bancorp Inc (ABP) lent almost $26 million since September 2021 and has gathered a broadened arrangement of solid credit quality. APB’s portfolio incorporates legislative securities, C&I stock, and land advancement credits. DSS invested $40 million in ABP during the Q3 of FY21, which has been very fruitful. This investment drove the advancement of their business pay model in a greater number of ways.

    DSS also declared that Impact BioMedical, the foundation of their bio-health group, advanced on various fronts in 2021. They expect to report the first license deal soon. The direct selling of the company expanded by $170 million with high benefits due to the shift to in-home shopping and the development of the gig economy.

    The CEO of DSS, Frank D. Heuszel, commented that simulated by advancement, industry needs, and acquisitions, they are centered around and prepared to enable the brands. He further added that they remain dedicated to wealth creation and accept that they have established an essential framework for future growth.

  • Ozon Holdings PLC (OZON) stock is losing in the pre-market. Here’s why

    The stock of Ozon Holdings PLC (OZON) closed the recent trading session at $11.6, losing 8.16% from the previous trading session. On the last check, the stock of OZON further lost 18.97% in the pre-market, to $9.4. The company discussed the effect of the embargo by the US, EU on its operations. The embargos on Russia acted as an inhibitor for the stock price.

    Ozon Holdings PLC is a Russian electronic trade company. The company interfaces and works with exchanges among purchasers and venders. Additionally, the company likewise sells items straightforwardly to their purchasers. With a market capitalization of $2.51 billion, the company has 216.41 million shares pending.

    OZON News

    On 24 February 2022, the firm notified about the progress of Ozon Bank. The company declared that the Ozon Bank was incorporated in the Specially Designated Nationals and Blocked Persons List by the OFAC of the U.S. treasury. Moreover, it documented an appeal to the OFAC of the U.S. Depository to eliminate Ozon Bank from the SDN list, on 25 February. Also, the company stated that Ozon Bank is not connected to Sovcombank.

    Due to the Russia-Ukraine conflict, the United States and European Union are putting embargos on Russia. These embargos are playing a key role in the decline in Russian company stocks. On 24 February 2022, Russia started the invasion of Ukraine. The firm discussed the effect of these embargos on their operation. The company stated that it is not liable for any embargos right now. Ozon additionally noticed that there are no administrative limitations on the capacity of U.S. people to get and exchange securities.

    The company further said that there is no immediate unfortunate impact of the U.S., EU, and different embargos on their present e-commerce operations and business. The company commented that they have a solid liquidity position with around 80% foreign liquidity. The organization had cash, cash equivalent, and short-term bank deposits of ₽126 billion as of December 31, 2021.

  • Novavax Inc (NVAX) stock lost 7.04% in the after-market. Here’s why

    The stock of Novavax Inc (NVAX) followed a bearish pattern in the after-market after releasing its financial outlook for Q4 and FY21. In the after-market, NVAX lost 7.04% to $77.5. NVAX closed the regular trading session at $83.37, gaining 2.13% from the previous trading session. The market capitalization of NVAX is $6.30 billion with 75.61 million shares pending.

    NVAX fiscal 2021

    On 28 February 2022, Novavax Inc released the financial performance for its Q4 and FY21, which concluded on 31 December 2021. Some important points are

    • The revenue for NVAX reduced by 20.5% to $222.2 million in Q4 of FY21 compared to $279.6 million in the corresponding period of last year. The yearly revenue grew by 141% from $475.5 million in 2020 to $1.14 billion in 2021.
    • The total loss of the company was reported to be $846.2 million in Q4 of FY21 in contrast to $177.5 million in Q4 of FY20. This marks a growth of 376.6% in the loss. The yearly loss was also up by 316.9% to $1.7 billion in 2021 versus $418.2 million in 2020.
    • The loss of $11.18 and $23.44 per stock in Q4 and FY21, respectively.

    Novavax Inc (NVAX) started the vaccine shipments worldwide in FY21. Also, NVAX extended clinical proof for NVX-CoV2373 across a few studies. Moreover, NVAX produced the COVID-19 vaccine, especially for the Omicron variant.

    NVAX News

    Also, On 28 February 2022, the company shared the expanded investigation from its Phase 3 clinical preliminary led in the United Kingdom (UK), showing a significant degree of adequacy for its protein-based COVID-19 vaccine, NVX-CoV2373. Further, the investigation showed immunization viability of 82.5% in assurance against all COVID-19 variants.

    The president of Research and Development, Gregory M. Glenn, commented that vaccine offers the defense against symptomatic and asymptomatic infection of COVID-19. He further added that the vaccine keeps an undeniable degree of sturdy adequacy.

    Fiscal 2022 outlook

    Novavax Inc (NVAX) estimated the revenue for FY22 to be in the range of $4 billion to $5 billion.

  • Vroom Inc (VRM) stock is losing in the after-market. Here’s why

    The stock of Vroom Inc (VRM) closed the regular trading session at $6.08, losing 1.94% from the previous trading session. On the last check, the stock of VRM remained bearish in the after-market, losing 7.4% to $5.63. Vroom Inc released the financial performance for the Q4 of its FY21. The company also filed form 8-K with the SEC on 28 February 2022.

    Vroom Inc focuses on the retail of cars. The firm deals in new and used vehicles, spare parts, and accessories. VRM also extends its services for repairs, financing, protection, and vehicle leasing. Currently, the company has a market capitalization of $832.41 million with 136.91 million pending shares. Vroom has its base in New York, United States of America (USA).

    VRM’s FY21

    Vroom Inc released the financial outlook for Q4 and FY21 on 28 February 2022. The sales of VRM were up 130% in Q4 of FY21 to $943.6 million compared to $405.8 over the corresponding period of last year. The yearly sales grew by 134% to $3.1 billion in 2021 versus $1.3 billion in 2020. In Q4 of FY21, the company earned a profit of $44.7 million compared to $20.1 million in the same period of FY20. This records an increase of 122%. The yearly profit also expanded by 182.4% to $202.1 million against $71.5 million in 2020. VRM had a total loss of $129.7 million in Q4 of FY21 versus $60.6 million in Q4 of FY20, expanding by 113.9%. Also, the yearly loss was up by 82% in 2021. Moreover, the company had a loss of $0.95 and $2.72 in Q4 and FY21, respectively.

    The units sold through the e-commerce platform were up by 93% to 0.02 million units. Also, the yearly units sold expanded by 117%.

    On 10 February 2022, Vroom Inc (VRM) also stated the cost of its auto loan. The company estimated an auto loan of $296.17 million in the total amount of auto receivable-backed notes.

    The CEO of VRM, Paul Hennessy, stated that he is pleased with what they have achieved in FY21. He further added that they anticipate the development of their business in 2022 as they welcome the new Chief Operating Officer, Tom Shortt.

    FY22 stance

    Vroom Inc (VRM) estimates the sales in Q1 of FY22 to be almost $875 million. The company estimated the e-commerce sale to be in the range of 18,000 to 19,000 units.

  • BP p.l.c. (BP) stock is losing in the pre-market. Here’s why

    BP p.l.c. (BP) stock is losing in the pre-market. Here’s why

    The stock of BP p.l.c. (BP) closed the recent trading session at $30.73, gaining 5.35% from the previous trading session. On the last check, the stock of BP lost 7.32% in the pre-market, to $28.48. The decline in the share price can be due to the news of BP quitting the shares in Rosneft. The firm declared that they would quit their shares in Rosneft. Rosneft is a Russian oil-producing company, which is located in Moscow, Russia.

    News

    On 27 February 2022, BP made an announcement about exiting the shareholding in the Russian oil-producing firm called as Rosneft. The company held 19.75% shares in Rosneft. The directors presented by BP will immediately resign from the Rosneft board. The report for Rosneft reserves, growth or gains will also not be made by BP. As per the chair of BP, this act is based on the Russian-Ukraine war. He stated that the attack by Russia on Ukraine is a demonstration of animosity which is having unfortunate outcomes across the area. He added that this military activity addresses a change. Further, the chair concluded that they can never again uphold bp agents holding a position on the Rosneft board.

    The CEO of the firm, Bernard Looney, commented that he has been profoundly stunned and disheartened by the circumstance unfurling in Ukraine. Further, he added that their prompt need is to focus on the individuals in the area and they will do their most extreme to help them. Mr. Looney was a director for Rosneft.

    After exiting the Rosneft, the company estimates to convey 7% to 9% of EBITDA per stock, through 2025 at oil costs of $50-60 for every barrel. The company also estimates the EBITDA to be in the range of $31 billion and $38 billion, for 2025.

    About BP

    BP Plc works as a coordinated oil and gas organization. Further, the firm is occupied with the worldwide energy business with Europe, North and South America, Asia, and Africa. BP through its scope of exercises conveys heat, light, and versatility items and services to clients. Also, the company has a market cap of $99.84 billion and 3.25 billion pending shares.

  • Mullen Automotive Inc (MULN) gained 54.06% in the pre-market. Here’s why

    Mullen Automotive Inc (MULN) gained 54.06% in the pre-market. Here’s why

    The stock Mullen Automotive Inc (MULN) closed the regular trading session at $0.68, gaining 11.15% from the previous trading session. The stock of MULN remained bullish in the pre-market, gaining 54.06% to $1.06. The gain in the stock price came after the company was featured by WardsAuto. Ward’s is an American firm that covers the auto business for 80 years, now.

    News

    On 24 February 2022, MULN broadcasted the latest publication by WardsAuto. The publication underlines the future plans of Mullen’s. This publication acted as a catalyst for the share price. The CEO of MULN, David Michery, stated that they are glad and grateful that industry chiefs like Wards are beginning to cover the EV exertion at Mullen. He also stated they had an incredible discussion about the enormous plans they have for FIVE electric vehicles.

    Mullen Automotive has reported collaboration with key organizations such as hofer powertrain, Comau, and DSA Systems. This collaboration aims towards EV powertrain, development, and Over the Air (OTA) testing. The company anticipates that these improvements should assume a critical part in putting up the FIVE for sale to the public. Mullen FIVE was also named “Top Zero Emission SUV” at the ZEVA awards in an international auto show in November 2021. Moreover, the FIVE is based on an electric vehicle hybrid skateboard programme.

    Moreover, on 17 February 2022, MULN proceeded with a letter to its investors. The letter underlines the performance of the firm. MULN is ready to launch its first electric vehicle cargo van expected in Q2. The superior performance adaptations of Mullen FIVE to show up later in summer 2022. The company has also filed for 120 patents. Also, successful finishing of broad customer study regarding EV market. Mullen FIVE scored high against Tesla Model Y and Ford Mach-E.

    About MULN

    Mullen Automotive Inc (MULN) is an EV organization. The firm is occupied with giving EV choices made to fit flawlessly for the consumer. Further, MULN has a market capitalization of $16.10 million and has 23.40 million pending stocks. The company has its base in Brea, California, United States of America (USA).